Healing effects of rebamipide and omeprazole in helicobacter pylori-positive gastric ulcer patients after eradication therapy

A randomized double-blind, multinational, multi-institutional comparative study

Kyung Ho Song, Yong Chan Lee, Dai Ming Fan, Zhi Zheng Ge, Feng Ji, Min Hu Chen, Hyun Chae Jung, Jiang Bo, Sang Woo Lee, Jin Ho Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Aims: A recent placebo-controlled trial showed that rebamipide, which is a mucosal-protective antiulcer agent, promoted gastric ulcer healing without affecting the Helicobacter pylori status. We conducted a randomized, double-blind trial to compare the healing effects of rebamipide and the proton-pump inhibitor omeprazole in H. pylori-positive gastric ulcers after H. pylori eradication therapy. Methods: After completion of 1 week of eradication therapy, 132 patients with H. pylori-positive gastric ulcer were enrolled in 5 Chinese and 4 Korean institutions. Patients were randomly assigned to take either 20 mg of omeprazole (n = 63) or 300 mg of rebamipide (n = 65) daily for 7 weeks. Healing was defined as complete recovery and S1 and S2 stage ulcer according to the Sakita-Miwa classification. Results: Healing rates at 12 weeks were 81.5% (53/65) and 82.5% (52/63) in the rebamipide and omeprazole groups, respectively. There was no significant difference in treatment efficacy, as evidenced by gastric ulcer healing rates (absolute difference-1.0%; 95% confidence interval-10.7 to 8.7; p = 0.88). The H. pylori eradication rate and ulcer healing rate did not differ between the groups, the latter regardless of eradication outcome. Conclusions: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.

Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalDigestion
Volume84
Issue number3
DOIs
Publication statusPublished - 2011 Oct 1

Fingerprint

Omeprazole
Stomach Ulcer
Helicobacter pylori
Ulcer
Therapeutics
Protective Agents
Proton Pump Inhibitors
rebamipide
Placebos
Confidence Intervals

Keywords

  • Gastric ulcer
  • Helicobacter pylori
  • Omeprazole
  • Proton pump inhibitor
  • Rebamipide
  • Treatment efficacy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Healing effects of rebamipide and omeprazole in helicobacter pylori-positive gastric ulcer patients after eradication therapy : A randomized double-blind, multinational, multi-institutional comparative study. / Song, Kyung Ho; Lee, Yong Chan; Fan, Dai Ming; Ge, Zhi Zheng; Ji, Feng; Chen, Min Hu; Jung, Hyun Chae; Bo, Jiang; Lee, Sang Woo; Kim, Jin Ho.

In: Digestion, Vol. 84, No. 3, 01.10.2011, p. 221-229.

Research output: Contribution to journalArticle

Song, Kyung Ho ; Lee, Yong Chan ; Fan, Dai Ming ; Ge, Zhi Zheng ; Ji, Feng ; Chen, Min Hu ; Jung, Hyun Chae ; Bo, Jiang ; Lee, Sang Woo ; Kim, Jin Ho. / Healing effects of rebamipide and omeprazole in helicobacter pylori-positive gastric ulcer patients after eradication therapy : A randomized double-blind, multinational, multi-institutional comparative study. In: Digestion. 2011 ; Vol. 84, No. 3. pp. 221-229.
@article{6fa7c657ade34e3fab1824078fd497b8,
title = "Healing effects of rebamipide and omeprazole in helicobacter pylori-positive gastric ulcer patients after eradication therapy: A randomized double-blind, multinational, multi-institutional comparative study",
abstract = "Background and Aims: A recent placebo-controlled trial showed that rebamipide, which is a mucosal-protective antiulcer agent, promoted gastric ulcer healing without affecting the Helicobacter pylori status. We conducted a randomized, double-blind trial to compare the healing effects of rebamipide and the proton-pump inhibitor omeprazole in H. pylori-positive gastric ulcers after H. pylori eradication therapy. Methods: After completion of 1 week of eradication therapy, 132 patients with H. pylori-positive gastric ulcer were enrolled in 5 Chinese and 4 Korean institutions. Patients were randomly assigned to take either 20 mg of omeprazole (n = 63) or 300 mg of rebamipide (n = 65) daily for 7 weeks. Healing was defined as complete recovery and S1 and S2 stage ulcer according to the Sakita-Miwa classification. Results: Healing rates at 12 weeks were 81.5{\%} (53/65) and 82.5{\%} (52/63) in the rebamipide and omeprazole groups, respectively. There was no significant difference in treatment efficacy, as evidenced by gastric ulcer healing rates (absolute difference-1.0{\%}; 95{\%} confidence interval-10.7 to 8.7; p = 0.88). The H. pylori eradication rate and ulcer healing rate did not differ between the groups, the latter regardless of eradication outcome. Conclusions: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.",
keywords = "Gastric ulcer, Helicobacter pylori, Omeprazole, Proton pump inhibitor, Rebamipide, Treatment efficacy",
author = "Song, {Kyung Ho} and Lee, {Yong Chan} and Fan, {Dai Ming} and Ge, {Zhi Zheng} and Feng Ji and Chen, {Min Hu} and Jung, {Hyun Chae} and Jiang Bo and Lee, {Sang Woo} and Kim, {Jin Ho}",
year = "2011",
month = "10",
day = "1",
doi = "10.1159/000329353",
language = "English",
volume = "84",
pages = "221--229",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Healing effects of rebamipide and omeprazole in helicobacter pylori-positive gastric ulcer patients after eradication therapy

T2 - A randomized double-blind, multinational, multi-institutional comparative study

AU - Song, Kyung Ho

AU - Lee, Yong Chan

AU - Fan, Dai Ming

AU - Ge, Zhi Zheng

AU - Ji, Feng

AU - Chen, Min Hu

AU - Jung, Hyun Chae

AU - Bo, Jiang

AU - Lee, Sang Woo

AU - Kim, Jin Ho

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Background and Aims: A recent placebo-controlled trial showed that rebamipide, which is a mucosal-protective antiulcer agent, promoted gastric ulcer healing without affecting the Helicobacter pylori status. We conducted a randomized, double-blind trial to compare the healing effects of rebamipide and the proton-pump inhibitor omeprazole in H. pylori-positive gastric ulcers after H. pylori eradication therapy. Methods: After completion of 1 week of eradication therapy, 132 patients with H. pylori-positive gastric ulcer were enrolled in 5 Chinese and 4 Korean institutions. Patients were randomly assigned to take either 20 mg of omeprazole (n = 63) or 300 mg of rebamipide (n = 65) daily for 7 weeks. Healing was defined as complete recovery and S1 and S2 stage ulcer according to the Sakita-Miwa classification. Results: Healing rates at 12 weeks were 81.5% (53/65) and 82.5% (52/63) in the rebamipide and omeprazole groups, respectively. There was no significant difference in treatment efficacy, as evidenced by gastric ulcer healing rates (absolute difference-1.0%; 95% confidence interval-10.7 to 8.7; p = 0.88). The H. pylori eradication rate and ulcer healing rate did not differ between the groups, the latter regardless of eradication outcome. Conclusions: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.

AB - Background and Aims: A recent placebo-controlled trial showed that rebamipide, which is a mucosal-protective antiulcer agent, promoted gastric ulcer healing without affecting the Helicobacter pylori status. We conducted a randomized, double-blind trial to compare the healing effects of rebamipide and the proton-pump inhibitor omeprazole in H. pylori-positive gastric ulcers after H. pylori eradication therapy. Methods: After completion of 1 week of eradication therapy, 132 patients with H. pylori-positive gastric ulcer were enrolled in 5 Chinese and 4 Korean institutions. Patients were randomly assigned to take either 20 mg of omeprazole (n = 63) or 300 mg of rebamipide (n = 65) daily for 7 weeks. Healing was defined as complete recovery and S1 and S2 stage ulcer according to the Sakita-Miwa classification. Results: Healing rates at 12 weeks were 81.5% (53/65) and 82.5% (52/63) in the rebamipide and omeprazole groups, respectively. There was no significant difference in treatment efficacy, as evidenced by gastric ulcer healing rates (absolute difference-1.0%; 95% confidence interval-10.7 to 8.7; p = 0.88). The H. pylori eradication rate and ulcer healing rate did not differ between the groups, the latter regardless of eradication outcome. Conclusions: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.

KW - Gastric ulcer

KW - Helicobacter pylori

KW - Omeprazole

KW - Proton pump inhibitor

KW - Rebamipide

KW - Treatment efficacy

UR - http://www.scopus.com/inward/record.url?scp=79960276727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960276727&partnerID=8YFLogxK

U2 - 10.1159/000329353

DO - 10.1159/000329353

M3 - Article

VL - 84

SP - 221

EP - 229

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 3

ER -